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Abstract
Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease nowadays. Certain cancers are more common in patients
with diabetes mellitus. However, there are no data concerning the cancer pattern in patients with DN. The aim of this study is to
investigate the site-speciﬁc cancer risk and mortality in these patients.
A retrospective cohort study of 5643 DN patients between 2000 and 2015 was conducted in 2 large hospitals in Hong Kong.
Incidence and mortality of various cancers were compared with those of general population using standardized incidence ratios
(SIRs) and standardized mortality ratios (SMRs) respectively.
With 24,726 person-years follow-up, 250 cancers were diagnosed. Overall cancer incidence was similar between DN patients and
the general population (SIR 1.05, 95% conﬁdence interval [CI] 0.92–1.19). However, certain site-speciﬁc cancers are increased in DN
patients: the highest risk was observed for laryngeal cancer (SIR 3.03, 95%CI 1.11–6.60), followed by cancers of liver (SIR 1.96, 95%
CI 1.35–2.76) and colorectum (SIR 1.92, 95% CI 1.53–2.37), but the risk of prostate cancer was lower (SIR 0.48, 95% CI 0.21–0.95)
in themales with DN. The SMR of all cancers was 1.17 (95%CI 1.01–1.37). For individual speciﬁc site, only colorectal cancer carried a
signiﬁcant higher mortality risk (SMR 2.45, 95% CI 1.82–3.23).
Our data suggested that DN is associated with increased incidence of cancers of colorectum, liver, and larynx but decreased
incidence of prostate cancer. Moreover, there is increased mortality of colorectal cancer in patients with DN.
Abbreviations: ACR = albumin to creatinine ratio, CDARS = Clinical Data Analysis and Reporting System, CKD = chronic kidney
disease, DM = diabeses mellitus, DN = diabetic nephropathy, ESKD = end-stage kidney disease, Hb = hemoglobin, MDRD =
modiﬁcation of diet in renal disease, PCR = protein to creatinine ratio, SD = standard deviation, SIR = standardized incidence ratio,
SMR = standardized mortality ratio.
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The prevalence of diabetes mellitus (DM) is increasing worldwide
with an aging population and lifestyle changes in many countries.
DM represents a major challenge in public health because it is
associated with many acute and chronic complications which
seriously affect the quality of life and survival of affected
individuals. The association between DM and cancer has been
studied extensively in the past and most of the studies showed
that certain types of cancer are more common in patients with
type 1 or type 2 DM.[1–8] In addition, DM has also been shown to
be associated with cancer mortality.[8,9]Editor: Sanket Patel.
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1Albuminuria is an early sign of diabetic nephropathy (DN),
which occurs in 25% to 40% of patients with DM.[10,11] DN is
now the leading cause of end-stage kidney disease (ESKD) in
different countries.[12] Various studies found that urinary
albumin excretion alone can predict cancer mortality even in
people without diabetes.[13,14] In addition, albuminuria has
been observed in patients with different types of cancers such
as colorectal, lung, renal cell, breast, and non-Hodgkin
lymphoma.[15–19]
Despite all these evidence, there are no data concerning the
cancer pattern in patients suffering from DN. The aim of our
study is to investigate the risk and mortality of various cancers in
patients suffering from DM associated nephropathy.
2. Methods
This is a retrospective cohort study in all patients with DN,
who had follow-up in the outpatient clinics of the Queen
Elizabeth Hospital and Queen Mary Hospital, 2 of the largest
hospitals in Hong Kong, between the period January 1, 2000
and December 31, 2015. Those patients with DN were
identiﬁed from the Clinical Data Analysis and Reporting
System (CDARS).
The CDARS is a tool developed by the Hospital Authority,
which is a statutory body responsible for primary, secondary, and
tertiary public healthcare services of Hong Kong. The database
generated from CDARS contains patients’ demographic data and
clinical information including diagnoses, operations, drug
prescriptions, laboratory investigations, inpatient stays, and
outpatient clinics since 1993. In addition, it also contains data on
Table 2
Standardized incidence ratios for all malignancies, stratiﬁed by
sex, age, and calendar year at diagnosis of DN.
Person-years O/E SIR (95% CI)
All patients 24,726 250/238.2 1.05 (0.92–1.19)
Sex
Male 13,940 157/149.0 1.05 (0.90–1.23)
Female 10,786 93/91.2 1.02 (0.82–1.25)
Age at diagnosis of DN, y
44 1131 2/1.1 1.82 (0.20–6.56)
45–64 10,985 49/50.7 0.97 (0.71–1.28)
≥65 12,610 199/186.4 1.07 (0.92–1.23)
Calendar year at diagnosis of DN
2000–2008 12,634 118/117.2 0.96 (0.79–1.16)
2009–2014 12,092 132/120.9 1.09 (0.91–1.29)
CI=conﬁdence interval, DN=diabetic nephropathy, E= expected number of cancer cases, based on
the general population in Hong Kong, from Hong Kong Cancer Registry, O=Observed number of
cancer cases, SIR= standardized incidence ratio.
Cheung et al. Medicine (2017) 96:38 Medicinecauses of death through its internal linkage to regional death
registry from the Immigration Department.
The inclusion criteria included reported primary or secondary
diagnosis of DM or requirement of medication for the treatment
of DM, together with the presence of macroalbuminuria or
proteinuria during screening for the diabetic complications.
Macroalbuminuria was determined by measuring the amount of
albumin in a spot urine sample and was deﬁned as the urinary
albumin to creatinine ratio (ACR) >30mg/mmol. However,
proteinuria could be detected by either spot urinary protein to
creatinine ratio (PCR)>0.5g/g (56mg/mmol) or 24-hour urinary
protein >0.5g.[20,21] The exclusion criteria included missing
values for determination of albuminuria or proteinuria; presence
of kidney diseases other than DN, and history of organ
transplants. The cohort entry date was deﬁned as the date of
DN when macroalbuminuria or proteinuria was ﬁrst diagnosed.
Basic demographic and clinical data including sex, age, diagnosis
of DM and cancers, amount of albuminuria and/or proteinuria,
hemoglobin (Hb) A1c, and serum creatinine level were extracted
from the CDARS and individual patient’s medical record.
Estimated glomerular ﬁltration rate was calculated by the
abbreviated MDRD equation (mL/min/1.73m2): 186 (creati-
nine/88.4)1.154 (age)0.203 (0.742 if female) (1.210 if
black).[22] All cancers were diagnosed with histology and other
relevant information, such as radiological imaging, and coded
according to the 10th World Health Organization International
Classiﬁcation of Disease (ICD-10). The follow-up duration was
deﬁned from the date of cohort entry to the date of death, the last
reported contact, or March 31, 2016. This study was approved
by the research ethics committee of both hospitals.2.1. Statistical Analyses
The statistical analyses were performed by SPSS (SPSS 20.0, Inc,
Chicago, IL). Categorical data were expressed as percentages and
continuous data were expressed as mean± standard deviation
(SD) or median (range). Categorical data were compared with x2
or Fisher exact tests, whereas continuous data were compared
with t test or Mann-Whitney U test. The outcome in this study
included the standardized incidence ratio (SIR) and the
standardized mortality ratio (SMR) of different cancers in
patients with DN. The SIR was calculated as the number of
observed cancer cases per 100,000 patient-years among the
patients with DN divided by the expected number of cancer cases
per 100,000 patient-years. The expected number of cases was
based on the age-adjusted cancer incidence rates in the general
population. All information about cancer incidence andmortality
in the Hong Kong general population could be obtained from the
Hong Kong Cancer Registry 2011.[23] The 95% conﬁdence
intervals of the SIRs were calculated by assuming that the
observed cancers follow a Poisson distribution. For patients with
multiple primary cancers, each tumor was counted separately inTable 1
Clinical characteristics of DN patients analyzed in the study.
All, n=5643
Male, n (%) 3215 (57.0)
Mean age at diagnosis of DN, y 66.3±11.5
Mean HbA1c (%) 7.9±0.7
Median albumin to creatinine ratio, mg/mmol 73.3 (30.0–1117.8)
Median proteinuria, g/day 1.6 (0.5–24.5)
DN=diabetic nephropathy.
2the analysis and the cancer would not be counted if it was
diagnosed before the onset of DN. However, the SMR was the
observed rate of cancer death among the patients with DN
divided by the expected rates of cancer death and the 95%
conﬁdence intervals (CIs) were also calculated by assuming that
the observed mortality follow a Poisson distribution. A P value of
<.05 was deﬁned as statistically signiﬁcant.3. Results
Total 6218patients were diagnosed to haveDMwith the presence
of macroalbuminuria or proteinuria during the study period.
Among them, 575 patients were excluded (425 with history of
kidney or liver transplants and 150 because of the presence of
other renal diseases). Thus, only 5643 patients were included in
the analysis. The clinical characteristics of these patients are
depicted in Table 1.
After a median follow -up duration of 4 years (6 months–16
years), 250 cancers were diagnosed. The overall cancer incidence
ratewas 4.4%. In the cancer group, the age at diagnosis of DNwas
68.0±10.7 years, whereas the age at diagnosis of cancer was 72.0
±9.7 years. There was no signiﬁcant difference in HbA1c, urinary
ACR, and amount of proteinuria between DN patients with and
without cancers (Table 1). Colorectal cancerwas themost common
cause of cancers in the patients withDN (34.0%), followed by lung
(16.4%), liver (13.2%), stomach (6.0%), and breast (5.6%).
The risks of any cancer occurrence were similar between
patients with DN and the age-matched general population (SIR
1.05, 95% CI 0.92–1.19). The SIRs of all cancers were then
further analyzed according to the sex, age at diagnosis of DN, and
year of diagnosis of DN (Table 2). However, there were also no
signiﬁcant differences in cancer risks among male and female
patients, age, and calendar year at the diagnosis of DN.Cancer, n=250 Non-cancer, n=5393 P
157 (62.8) 3058 (56.7) .06
68.0±10.7 65.8±10.5 .10
8.0±1.7 7.9±0.9 .47
67.9 (30.5–1026.4) 74.3 (30.0–1117.8) .56
1.7 (0.5–17.6) 1.4 (0.5–24.5) .13
[24–26]
Table 5
Standardized mortality ratio of the commonest sites of cancer
deaths in patients with DN.
Site of cancer O/E SMR (95% CI)
Colorectal 50/20.4 2.45 (1.82–3.23)
Lung 36/42.4 0.85 (0.59–1.17)
Liver 20/15.4 1.30 (0.79–2.01)
Esophagus 8/3.8 2.11 (0.91–4.15)
Pancreas 8/5.1 1.57 (0.68–3.09)
CI=conﬁdence interval, DN=diabetic nephropathy, E= expected number of cancer cases, based on
the general population in Hong Kong, from Hong Kong Cancer Registry, O= observed number of
cancer cases, SMR= standardized mortality ratio.
Table 3
Percentage of different cancer sites and site-speciﬁc cancer risk
in all patients with DN.
Site of cancer Percentage O/E SIR (95% CI)
Colorectal 34.0 85/44.3 1.92 (1.53–2.37)
Lung 16.4 41 /47.9 0.86 (0.61–1.16)
Liver 13.2 33 /16.8 1.96 (1.35–2.76)
Stomach 6.0 15/11.3 1.33 (0.74–2.19)
Breast 5.6 14/18.7 0.75 (0.41–1.26)
Esophagus 3.2 8/4.7 1.72 (0.74–3.39)
Nasopharynx 3.2 8/5.0 1.67 (0.72–3.29)
Pancreas 3.2 8/5.3 1.50 (0.65–2.96)
Prostate 3.2 8/16.7 0.48 (0.21–0.95)
Larynx 2.4 6/1.9 3.03 (1.11–6.60)
NHL 1.6 4/6.5 0.62 (0.17–1.59)
Oral cavity 1.2 3/4.6 0.65 (0.13–1.91)
Bladder 1.2 3/5.3 0.57 (0.11–1.66)
Kidney 0.8 2/3.9 0.51 (0.06–1.85)
Multiple myeloma 0.8 2/2.3 0.87 (0.10–3.13)
CI= conﬁdence interval, DN=diabetic nephropathy , E= expected number of cancer cases, based on
the general population in Hong Kong, from Hong Kong Cancer Registry, NHL=non-Hodgkin
lymphoma, O= observed number of cancer cases, SIR= standardized incidence ratio.
Cheung et al. Medicine (2017) 96:38 www.md-journal.comTable 3 showed the SIRs of the major cancer sites. Highest risk
was observed for laryngeal cancer (SIR 3.03, 95%CI 1.11–6.60),
followed by cancers of liver (SIR 1.96, 95% CI 1.35–2.76) and
colorectum (SIR 1.92, 95% CI 1.53–2.37). All patients with
laryngeal cancer were males. For cancers of liver and colorectum,
the incidence was increased in both male and female patients
(Table 4). However, the risk of prostate cancer was lower (SIR
0.48, 95% CI 0.21–0.95) in the males with DN.
Total 162 patients died of cancer during the study period. The
cancer mortality risk was higher in patients with DN when
compared with the general population (SMR 1.17, 95% CI
1.01–1.37). When the SMR of all cancers was further analyzed
according to sex, the SMR of male and female patients was 1.18
(95% CI 0.96–1.42) and 1.08 (95% CI 0.82–1.41), respectively.
The SMR of common cancer sites were shown in Table 5.4. Discussion
The association between DM and the risk of various cancers has
been extensively investigated. A number of studies have suggested
that DM can increase the risk of several cancers such as
pancreatic cancer,[4] liver cancer,[5] colorectal cancer,[6] breast
cancer,[7] and kidney cancer,[8] but the exact reasons for the
increased risk of these cancers are still a matter of debate.
Different mechanisms have been proposed to explain the
relationship between DM and risk of cancer. Type 2 DM is
associated with relative insulin insufﬁciency and is characterized
by hyperinsulinemia and insulin resistance. Insulin is a growth
factor which can promote proliferation of cancer cells. Therefore,Table 4
Site-speciﬁc cancer risk of commonest cancers in male and female
Site of cancer Male O/E SIR (95%
Colorectal 50/27.5 1.82 (1.35–2
Lung 33/34.6 0.95 (0.66–1
Liver 23/13.6 1.69 (1.07–2
Stomach 10/7.7 1.30 (0.62–2
CI= conﬁdence interval, DN=diabetic nephropathy, E= expected number of cancer cases, based on the g
observed number of cancer cases, SIR= standardized incidence ratio.
3hyperinsulinemia can have a direct carcinogenic effect. In
addition, hyperinsulinemia may also increase the level of insulin-
like growth factor axis protein 1, which is a potential mitogen
and inhibitor of apoptosis and can promote tumorigenesis.[27–29]
Furthermore, type 2 DM and cancers share many common risk
factors such as age, obesity, tobacco use, and higher intake of
saturated fats. As a result, both insulin resistance and shared risk
factors can explain the association between type 2DMand risk of
cancer development. However, type 1 DM is a condition caused
by the autoimmune destruction of the beta cells within the
pancreas. The evidence of the association between type 1DMand
cancer is limited and variable, depending on the researchmethods
used and the criteria for the diagnosis of DM.[30] In a recent study
using one of the largest diabetes registries, the magnitudes of
excess risk of cancers for type 1 and type 2 DM are generally
similar, supporting the concept that hyperglycemia, found in
both types of DM, can be themechanistic driver betweenDMand
cancers.[8]
Despite all the available clinical evidence, there are no data
concerning the cancer pattern and the risk of various cancers in
patients with DN. The classic renal pathology of DN, no matter
whether it is caused by type 1 or type 2 DM, is the presence of
different pathological lesions of diabetic glomerulosclerosis.
These lesions could then lead to albuminuria. Albuminuria
assessment is commonly used for early diagnosis and screening of
DN. Microalbuminuria may be regarded as an early marker of
DN and can be deﬁned as appearance of small amounts of
albumin in urine (30–300mg/day in 24-hour collection or spot
urine ACR 3–30mg/mmol). However, macroalbuminuria is
deﬁned as an ACR >30mg/mmol. Two of 3 samples should fall
within the microalbuminuric or macroalbuminuric range to
conﬁrm the classiﬁcation.[20] Without speciﬁc interventions,
approximately 80% of patients with type 1 DM who developed
sustained microalbuminuria will progress to the stage of
macroalbuminuria or overt nephropathy during a period of 10
to 15 years. ESKD develops in 50% of type 1 diabetic patients
with overt nephropathy within 10 years and in >75% by 20
years. However, 20% to 40% of type 2 diabetic patients withpatients with DN.
CI) Female O/E SIR (95% CI)
.40) 35/17.7 1.98 (1.38–2.75)
.34) 8/14.9 0.54 (0.23–1.06)
.54) 10/4.3 2.31 (1.11–4.26)
.38) 5/3.9 1.29 (0.42–3.02)
eneral population in Hong Kong, from Hong Kong Cancer Registry, NHL=non-Hodgkin lymphoma, O=
Cheung et al. Medicine (2017) 96:38 Medicinemicroalbuminuria progress to overt nephropathy and only 20%
will further progress to ESKD by 20 years after onset of overt
nephropathy.[31] It has been found that each SD increase in
albuminuria could result in a 20% increase in the overall risk of
cancer even in patients without DM.[10] Moreover, a study in
Taiwan showed that presence of proteinuria could predict 10-
year cancer-related mortality in patients with type 2 DM.[32]
However, another study based on a cohort from a randomized
trial showed that mild to moderate chronic kidney disease (CKD)
did not increase the risk of cancer in people with DM.[33]
To the best of our knowledge, ours is the ﬁrst cohort study
investigating the risk of various cancers in patients with DM-
associated nephropathy when compared with the general
population. We could not ﬁnd any signiﬁcant association
between DN and an increased incidence of overall cancer.
However, there were increased risks of certain site-speciﬁc
cancers such as cancers of larynx, liver, and colorectum in our
cohort. Positive association of laryngeal cancer with either DMor
CKDwas rarely reported in literature. A prospective cohort study
in Japan observed a positive association of DM with laryngeal
cancer in men.[34] As all the patients with laryngeal cancer in our
cohort were males, the SIR of laryngeal cancer in men with DN
was 2.94 (95% CI 1.07–6.40). As the number of patients is small
and confounding factors such as smoking status are not known,
further studies are required to ascertain this positive association.
In addition, our ﬁndings also indicated that patients with DN
had a higher incidence of liver cancer (SIR 1.96, 95% CI
1.35–2.76) and colorectal cancer (SIR 1.92, 95% CI 1.53–2.37)
when compared with the general population. In fact, the positive
association between both cancers and DM has been well
documented in literature.[5,6] In a meta-analysis, the incidence
of liver cancer was higher in individuals with DM (SIRs=2.01,
95% CI: 1.61–2.51), compared with those without DM.[5]
Moreover, DM was associated with an increased risk of
colorectal cancer, compared with no DM (SIR 1.30, 95% CI
1.20–1.40).[6] However, we observed a lower risk of prostate
cancer in our cohort. This is in concordance with some studies in
patients with DM[8] and the reason can be owing to the lower
levels of circulating testosterone in these individuals.[35] Unlike
some other studies, we did not ﬁnd any signiﬁcant association
between DN and cancers of pancreas, breast, or kidneys.
The overall risk of cancer death in patients with DN was
signiﬁcantly higher than the age- and sex-matched population in
our study. However, among the different cancers identiﬁed in our
cohort, only colorectal cancer had higher cancer mortality than
the general population (SMR 2.45, 95% CI 1.82–3.23).
Proteinuria has been found to be associated with cancer-related
mortality (hazard ratio 1.99; 95% CI 1.00–3.94). In addition,
proteinuria also showed a trend of increased colon cancer
death.[30] The exact mechanisms for the association between
proteinuria and cancer mortality remain unclear. One possible
explanation is that proteinuria is associated with low-grade
inﬂammation in DM, which can increase the risk of cancer.[36]
There are several strengths in this study. First of all, our study
has the largest patient-years of follow up in studying the
relationship between DN and cancers. Moreover, an accurate
ascertainment of those patients with DN and cancers was
possible by linking the various data in the CDARS. The database
generated from CDARS has been used to conduct high-quality
epidemiological studies in the past.[37,38] In addition, the cancer
data obtained from the Hong Kong Cancer Registry are also of
high standard. The percentage of histologically veriﬁed cases and
death certiﬁcate only cases (the 2 key performance indicators of4data completeness) was 87% and 0.7%, respectively. This is
already up to the highest International Association of Cancer
Registries standard for developed countries [23]
However, there are a number of limitations in our study. First
of all, it was a retrospective study and various risk factors of
cancers such as obesity, tobacco use, alcohol consumption, and
family history of cancers were not recorded. In addition, DM
itself is not a single disease, but can be viewed as a group of
metabolic disorders characterized by hyperglycemia. A series of
potential confounders directly related to DM such as obesity,
diet, and physical activity were not available in our study.
Moreover, the diagnosis of DN might be underestimated in our
study because it was based on the presence of albuminuria only.
Although the natural history of DN has been described as
progressive albuminuria followed by a steady loss of GFR, there
are studies showing that patients with DN can have a reduced
GFR without albuminuria.[39] In our study, presence of
albuminuria was assessed using a single specimen. As albumin-
uria can be transient or reversible, only those patients with
macroalbuminuria and/or proteinuria were included. It has been
known that transient hyperglycemia, urinary tract infections,
exercise within 24hours, severe hypertension, congestive heart
failure, and acute febrile illness can all cause transient micro-
albuminuria. Some studies have shown that although all
individuals with macroalbuminuria in the ﬁrst urine sample
had either macroalbuminuria or microalbuminuria in the second
urine sample, approximately one-third of the adults with
microalbuminuria would not have increased urine albumin
excretion on repeat assessment.[39,40] Furthermore, wemight also
miss some patients with DN who had improvement of
albuminuria or proteinuria after the use of angiotensin-convert-
ing enzyme inhibitors or angiotensin receptor blockers. As we
only focused on those patients with DN, the size of our cohort
was relatively small and there was insufﬁcient power to provide
sex-speciﬁc estimates of each cancer from this study. In addition,
the ﬁndings in our study might not be able to be generalized to
other populations because the cancer risk was different among
diabetic patients of different ethnicities.[41] Finally, the informa-
tion concerning the use of antidiabetic medication such as
metformin, which has been found to be associated with reduced
risk of cancers in some studies, were not included in our
analysis.[42,43]
In conclusion, we demonstrate that DN is associated with
increased incidence of cancers of colorectum, liver, and larynx
but decreased incidence of prostate cancer. Moreover, there is
also increased mortality of colorectal cancer in patients with DN.
As most of the patients in this study are Chinese, further studies
are required to see whether similar association can also be found
in other populations.
Our manuscript is a unique submission and is not being
considered for publication by any other source in any medium.
Further, the manuscript has not been published, in part or in full,
in any form.
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